Our investment case EXPERIENCED MANAGEMENT TEAMS WITH A PROVEN TRACK RECORD Our experienced management teams have a long historyof delivering strong growth.
Since listing on the London Stock Exchange in 2005, we have grown revenue at a compound annual rate of 20%, from $262 million to around $2.0 billion in 2016.
Over the same period, Hikmas market capitalisation has increased from $0.9 billion to $5.6 billion, firmly establishing Hikma as a leading global pharmaceutical company, and wehave delivereda total shareholder return of 343%.
We continue to set ourselves ambitious targets for future growth, which will be delivered through strong organic growth and further strategic acquisitions.
Revenue $ million $1,950m 1,950 1,489 1,440 14 15 16 Hikma Pharmaceuticals PLC 14 Strategic report Corporate governance Financial statements Annual Report 2016 15
